AU2007260985A1 - Imidazolidinone Kv1.5 potassium channel inhibitors - Google Patents

Imidazolidinone Kv1.5 potassium channel inhibitors Download PDF

Info

Publication number
AU2007260985A1
AU2007260985A1 AU2007260985A AU2007260985A AU2007260985A1 AU 2007260985 A1 AU2007260985 A1 AU 2007260985A1 AU 2007260985 A AU2007260985 A AU 2007260985A AU 2007260985 A AU2007260985 A AU 2007260985A AU 2007260985 A1 AU2007260985 A1 AU 2007260985A1
Authority
AU
Australia
Prior art keywords
methoxyphenyl
ethyl
imidazolidinone
phenyl
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2007260985A
Other languages
English (en)
Inventor
Benjamin E. Blass
Gregory Kent Bosch
Neil T. Fairweather
Stephen Joseph Hodson
Christopher M. Jackson
John Michael Janusz
Ronald Eugene White
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of AU2007260985A1 publication Critical patent/AU2007260985A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C07D233/38—One oxygen atom with acyl radicals or hetero atoms directly attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2007260985A 2006-06-20 2007-06-19 Imidazolidinone Kv1.5 potassium channel inhibitors Abandoned AU2007260985A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81509106P 2006-06-20 2006-06-20
US60/815,091 2006-06-20
PCT/US2007/071587 WO2007149874A1 (en) 2006-06-20 2007-06-19 Imidazolidinone kv1.5 potassium channel inhibitors

Publications (1)

Publication Number Publication Date
AU2007260985A1 true AU2007260985A1 (en) 2007-12-27

Family

ID=38582320

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007260985A Abandoned AU2007260985A1 (en) 2006-06-20 2007-06-19 Imidazolidinone Kv1.5 potassium channel inhibitors

Country Status (20)

Country Link
US (2) US7504517B2 (enExample)
EP (1) EP2035392A1 (enExample)
JP (1) JP2009541343A (enExample)
KR (1) KR20090021223A (enExample)
CN (1) CN101573341A (enExample)
AR (1) AR061523A1 (enExample)
AU (1) AU2007260985A1 (enExample)
BR (1) BRPI0713320A2 (enExample)
CA (1) CA2655574A1 (enExample)
CL (1) CL2007001794A1 (enExample)
CO (1) CO6150173A2 (enExample)
CR (1) CR10527A (enExample)
EC (1) ECSP088994A (enExample)
MX (1) MX2008016399A (enExample)
NO (1) NO20085252L (enExample)
PE (1) PE20080942A1 (enExample)
RU (1) RU2008150465A (enExample)
TW (1) TW200815363A (enExample)
WO (1) WO2007149874A1 (enExample)
ZA (1) ZA200810763B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2007001794A1 (es) * 2006-06-20 2008-01-18 Wyeth Corp Compuestos derivados de 2-imidazolidinona, inhibidores del canal de potasio kv1.5; composicion farmaceutica que los comprende; y su uso para tratar o prevenir arritmias cardiacas. tromboembolia,apoplejia,insuficiencia cardiaca.
RU2373934C1 (ru) * 2008-03-19 2009-11-27 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Применение производных глутаровой кислоты или их фармацевтически приемлемых солей в качестве противоаритмических средств
CN101544580B (zh) * 2009-04-28 2019-03-15 大连凯飞精细化工有限公司 R-alpha-氨基-4-甲氧基苯乙酰胺的合成方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4099009A (en) * 1977-04-11 1978-07-04 Morton-Norwick Products, Inc. 1-(4-chlorophenyl)-3-(1-ureido)-2-imidazolidinone
SK94393A3 (en) 1992-09-11 1994-08-10 Thomae Gmbh Dr K Cyclic derivatives of urea, process for their production and their pharmaceutical agents with the content of those
DE4332168A1 (de) 1993-02-22 1995-03-23 Thomae Gmbh Dr K Cyclische Derivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
CA2243121A1 (en) 1996-01-26 1997-07-31 Francesco Gerald Salituro Aspartyl protease inhibitors
AU716153B2 (en) 1996-04-03 2000-02-17 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US7129359B2 (en) * 2002-07-09 2006-10-31 National Health Research Institutes Imidazolidinone compounds
BR0214437A (pt) 2001-11-30 2004-10-13 Lilly Co Eli Composto, composição farmacêutica, métodos de modular um receptor ativado por proliferador de peroxissoma, de tratar e de prevenir a diabete melito, e de tratar a sìndrome x, e doenças cardiovasculares em um mamìfero, e, uso de um composto
WO2003057214A1 (en) 2001-12-28 2003-07-17 Somatocor Pharmaceuticals, Inc. Imidazolidin-2,4-dione derivatives as non-peptide somatostatin receptor ligands
WO2004046137A1 (en) 2002-11-21 2004-06-03 Vicore Pharma Ab New tricyclic angiotensin ii agonists
JP2004262903A (ja) 2003-03-04 2004-09-24 Japan Science & Technology Agency アジリジン類の製造方法
US7259174B2 (en) * 2004-05-25 2007-08-21 National Health Research Institutes Imidazolidinone compounds
AR050858A1 (es) 2004-09-07 2006-11-29 Glaxo Group Ltd Compuesto de heteroaril-nitrilo sustituido, su uso para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para la preparacion del mismo
KR100677149B1 (ko) * 2004-11-12 2007-02-02 삼성전자주식회사 잉크 조성물
CL2007001794A1 (es) * 2006-06-20 2008-01-18 Wyeth Corp Compuestos derivados de 2-imidazolidinona, inhibidores del canal de potasio kv1.5; composicion farmaceutica que los comprende; y su uso para tratar o prevenir arritmias cardiacas. tromboembolia,apoplejia,insuficiencia cardiaca.

Also Published As

Publication number Publication date
CR10527A (es) 2009-02-19
WO2007149874A1 (en) 2007-12-27
WO2007149874A8 (en) 2008-03-20
BRPI0713320A2 (pt) 2012-02-07
ECSP088994A (es) 2009-01-30
US7803827B2 (en) 2010-09-28
RU2008150465A (ru) 2010-07-27
EP2035392A1 (en) 2009-03-18
NO20085252L (no) 2009-01-13
MX2008016399A (es) 2009-02-03
CN101573341A (zh) 2009-11-04
US20090069342A1 (en) 2009-03-12
CA2655574A1 (en) 2007-12-27
CO6150173A2 (es) 2010-04-20
US7504517B2 (en) 2009-03-17
AR061523A1 (es) 2008-09-03
TW200815363A (en) 2008-04-01
JP2009541343A (ja) 2009-11-26
US20070299120A1 (en) 2007-12-27
CL2007001794A1 (es) 2008-01-18
KR20090021223A (ko) 2009-02-27
ZA200810763B (en) 2009-09-30
PE20080942A1 (es) 2008-09-03

Similar Documents

Publication Publication Date Title
US12503458B2 (en) 5-hydroxytryptamine receptor 7 activity modulators and their method of use
AU2022202240B2 (en) Novel modulators of the 5-hydroxytryptamine receptor 7 and their method of use
US12338245B2 (en) 5-hydroxytryptamine receptor 7 modulators and their use as therapeutic agents
US10544117B2 (en) 5-hydroxytryptamine receptor 7 activity modulators and their method of use
US9464062B2 (en) Disubstituted oxazolidin-2-ones 5-hydroxytryptamine receptor 2B activity modulators
AU2007260984A1 (en) Kv1.5 potassium channel inhibitors
US7803827B2 (en) Kv1.5 potassium channel inhibitors
JP2011507883A (ja) Ｋｖ１．５カリウムチャネル阻害剤としての４−イミダゾリジノン
CA2898574A1 (en) Novel functionalized 4-(phenoxymethyl)-1,3-dioxolane analogs exhibiting cytochrome p450 inhibition and their method of use
AU2002334771A1 (en) Spiro-hydantoin compounds useful as anti-inflammatory agents

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period